DMK PHARMACEUTICALS Corp: Nasdaq/NYSE listing notice — Adamis Pharmaceuticals receives Nasdaq deficiency notice for MVLS below $35M

DMK PHARMACEUTICALS Corp

Nasdaq notice on April 12, 2023: Market Value of Listed Securities below $35M for 30 consecutive business days.
Company has until Oct 9, 2023 to regain compliance by achieving MVLS >= $35M for 10 consecutive business days.
If not compliant by deadline, Nasdaq will issue delisting notice; company may appeal.
No immediate impact on listing or trading of common stock (ADMP).

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

DMK PHARMACEUTICALS Corp received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

April 12, 2023, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). The Notice is only a notification of deficiency, not of imminent delisting

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001387131-23-004783

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.